Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

["Triple negative" breast cancer].

P Freres¹, J Collignon, C Gennigens

¹Université de Liège.

Revue Medicale De Liege

|April 24, 2010

Summary

Breast cancer incidence is rising, but mortality is decreasing due to early diagnosis and new therapies. Triple-negative breast cancer, however, remains aggressive with limited treatment options.

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy of olaparib in advanced cancers with somatic or germline mutations in BAP1, BARD1, BRIP1 and PALB2.

ESMO open·2026

Same author

Trastuzumab deruxtecan in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer (DESTINY-Breast06): outcome analyses by time to progression on prior first-line endocrine therapy with CDK4/6 inhibitor and baseline burden of disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2026

Same author

A phase IV prospective study of efficacy and safety of ribociclib and letrozole as first-line therapy in older women (≥70 years) with hormone receptor-positive HER2-negative advanced breast cancer: the RibOB study.

ESMO open·2026

Same author

Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2024

Same author

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.

ESMO open·2023

Same author

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.

Breast cancer research : BCR·2023

Area of Science:

Oncology
Genetics

Background:

Breast cancer affects 1 in 8 women in Western countries, remaining a leading cause of cancer death in women under 65.
While overall breast cancer mortality is decreasing due to advancements in therapy and early detection, aggressive subtypes pose significant challenges.

Observation:

Triple-negative breast cancer (TNBC), representing 10% of all breast cancers, lacks estrogen, progesterone, and HER2 receptors.
This subtype is associated with a poor prognosis and a high rate of early metastatic recurrence.

Findings:

Currently, no targeted therapies are available for triple-negative breast cancer.
The absence of specific biomarkers makes treatment selection difficult for TNBC patients.

Implications:

Related Experiment Videos

Last Updated: Jun 13, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

Identifying novel therapeutic targets for TNBC is crucial for improving patient outcomes.

Predicting tumor response to different treatments is essential for developing personalized therapeutic strategies for this aggressive breast cancer subtype.